Sheila Gujrathi

2.7k total citations · 1 hit paper
30 papers, 1.9k citations indexed

About

Sheila Gujrathi is a scholar working on Molecular Biology, Genetics and Rheumatology. According to data from OpenAlex, Sheila Gujrathi has authored 30 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Genetics and 7 papers in Rheumatology. Recurrent topics in Sheila Gujrathi's work include Sphingolipid Metabolism and Signaling (10 papers), Inflammatory Bowel Disease (8 papers) and Liver Diseases and Immunity (5 papers). Sheila Gujrathi is often cited by papers focused on Sphingolipid Metabolism and Signaling (10 papers), Inflammatory Bowel Disease (8 papers) and Liver Diseases and Immunity (5 papers). Sheila Gujrathi collaborates with scholars based in United States, Canada and Belgium. Sheila Gujrathi's co-authors include Allan Olson, Paul Frohna, Richard Aranda, William J. Sandborn, Heather Smith, Allison Luo, Jeffrey Hartung, Subrata Ghosh, Geert D’Haens and Séverine Vermeire and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Neurology.

In The Last Decade

Sheila Gujrathi

29 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

2016 360 citations William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Sheila Gujrathi

Since Specialization

Citations

This map shows the geographic impact of Sheila Gujrathi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheila Gujrathi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheila Gujrathi more than expected).

Fields of papers citing papers by Sheila Gujrathi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheila Gujrathi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheila Gujrathi. The network helps show where Sheila Gujrathi may publish in the future.

Co-authorship network of co-authors of Sheila Gujrathi

This figure shows the co-authorship network connecting the top 25 collaborators of Sheila Gujrathi. A scholar is included among the top collaborators of Sheila Gujrathi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheila Gujrathi. Sheila Gujrathi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P1097 Phase 1/2 study to assess safety, tolerability, and efficacy of XmAb942 (anti-TL1A) in healthy participants and participants with ulcerative colitis 2025 ·Journal of Crohn s and Colitis ·Kenneth E. Hung, S. Aggarwal, Sharron Gargosky, Christopher Peterson, Saroja Ramanujan, (unknown), Zorayr Manukyan, Mina Hassan‐Zahraee, Jitendra Kanodia, Jessica G. Woo, David E. Szymkowski, S Visonneau, Bart Burington, Christina Trout, Dario Leone, Bassil I. Dahiyat, Sheila Gujrathi, John R. Desjarlais	0
2	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial 2016 ·The Lancet Neurology ·Jeffrey A. Cohen, Douglas L. Arnold, Cristoforo Comi, Amit Bar‐Or, Sheila Gujrathi, Jeffrey Hartung, Matt Cravets, Allan Olson, Paul Frohna, Krzysztof Selmaj	144
3	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis breakdown → 2016 ·New England Journal of Medicine ·William J. Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert D’Haens, Séverine Vermeire, Stephen B. Hanauer, Subrata Ghosh, Heather Smith, Matthew Cravets, Paul Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson	360
4	Efficacy Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Adults with Relapsing Multiple Sclerosis (P7.198) 2015 ·Neurology ·Gıancarlo Comı, Jeffrey A. Cohen, Douglas L. Arnold, Amit Bar‐Or, Sheila Gujrathi, Jeffrey Hartung, Allan Olson, Matthew Cravets, Paul Frohna, Krzysztof Selmaj	5
5	Safety and Tolerability Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Relapsing Multiple Sclerosis (P7.199) 2015 ·Neurology ·Krzysztof Selmaj, Douglas L. Arnold, Gıancarlo Comı, Amit Bar‐Or, Sheila Gujrathi, Jeffrey Hartung, Allan Olson, Matthew Cravets, Paul Frohna, Jeffrey A. Cohen	1
6	Absence Of A Relevant Effect On Cardiac Repolarization In A QT/QTc (TQT) Study of RPC1063, A Novel, Selective S1P1 Receptor Agonist, In Healthy Adult Volunteers (P2.229) 2014 ·Neurology ·Jeffrey Hartung, Allan Olson, Robert Peach, Marcus F. Boehm, Boaz Mendzelevski, Heather Smith, (unknown), Gregg Timony, Sheila Gujrathi	1
7	Pharmacokinetics and Pharmacodynamics of RPC1063 and Its Metabolites in Healthy Adult Volunteers (P1.211) 2014 ·Neurology ·Gregg Timony, (unknown), Jeffrey Hartung, Fiona L. Scott, Allan Olson, Sheila Gujrathi, Marcus F. Boehm, Robert Peach	4
8	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study 2013 ·Gut ·Lloyd Mayer, William J. Sandborn, (unknown), Karel Geboes, Robert Hardi, Michael Yellin, Xiaolu Tao, (unknown), Luisa Salter–Cid, Sheila Gujrathi, Richard Aranda, Allison Luo	119
9	Safety and Tolerability of Orally Administered RPC1063, a Novel S1P1 Receptor Modulator, in Healthy Adult Volunteers, Results of a Phase 1 Study (P01.178) 2013 ·Neurology ·Allan Olson, Jeffrey Hartung, Gregg Timony, Robert Peach, Marcus F. Boehm, Hugh Rosen, Heather Smith, (unknown), Jennifer L. Brooks, Sheila Gujrathi	5
10	Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program 2013 ·The Journal of Rheumatology ·Michael E. Weinblatt, Larry W. Moreland, René Westhovens, Roger B. Cohen, Sheila Kelly, Nader Khan, R. Pappu, I. Delaet, Allison Luo, Sheila Gujrathi, Marc C. Hochberg	104
11	Abatacept for Crohn's Disease and Ulcerative Colitis 2012 ·Gastroenterology ·William J. Sandborn, Jean‐Frédéric Colombel, Bruce E. Sands, Paul Rutgeerts, Stephan R. Targan, Remo Panaccione, Brian Bressler, K. Geboes, Stefan Schreiber, Richard Aranda, Sheila Gujrathi, Allison Luo, Yun Peng, Luisa Salter–Cid, Stephen B. Hanauer	111
12	Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study 2012 ·Annals of the Rheumatic Diseases ·Edward Keystone, Joel M. Kremer, Anthony S. Russell, J. Box, Carlos Abud‐Mendoza, Mario Alberto Garza‐Elizondo, Allison Luo, Richard Aranda, I. Delaet, René Swanink, Sheila Gujrathi, Michael E. Luggen	43
13	Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies) 2011 ·Transplantation ·Yves Vanrenterghem, Barbara A. Bresnahan, Josep M. Campistol, Antoine Dürrbach, Josep M. Grinyó, Hans‐Hellmut Neumayer, Philippe Lang, Christian P. Larsen, Eduardo Mancilla-Urrea, José Medina‐Pestana, A. Jay Block, Tao Duan, (unknown), Sheila Gujrathi, Flavio Vincenti	134
14	Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study) 2011 ·Annals of the Rheumatic Diseases ·Jeffrey Kaine, (unknown), Ingrid Strusberg, (unknown), Ingrid Louw, Sheila Gujrathi, R. Pappu, I. Delaet, Miranda Pans, Charles Ludivico	63
15	Five-Year Safety and Efficacy of Belatacept in Renal Transplantation 2010 ·Journal of the American Society of Nephrology ·Flavio Vincenti, Gilles Blancho, Antoine Dürrbach, Peter J. Friend, Josep M. Grinyó, Philip F. Halloran, Jürgen Klempnauer, Philippe Lang, Christian P. Larsen, Ferdinand Mühlbacher, Björn Nashan, Jean‐Paul Soulillou, Yves Vanrenterghem, Thomas Wekerle, Mamta Agarwal, Sheila Gujrathi, (unknown), Rebecca Shi, Robert Townsend, Bernard Charpentier	145
16	An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients 2010 ·Transplantation ·Josep M. Grinyó, Bernard Charpentier, José Medina‐Pestana, Yves Vanrenterghem, Flavio Vincenti, Rafael Reyes‐Acevedo, Anne Marie Apanovitch, Sheila Gujrathi, Mamta Agarwal, Dolca Thomas, Christian P. Larsen	86
17	Targeting lymphocyte co-stimulation: From bench to bedside 2010 ·Autoimmunity ·Nathan Felix, Anish Suri, Luisa Salter–Cid, Steven G. Nadler, Sheila Gujrathi, M Corbo, Richard Aranda	26
18	Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study 2008 ·Arthritis & Rheumatism ·Mark C. Genovese, Jeffrey Kaine, Mitchell B. Lowenstein, (unknown), Andrew R. Baldassare, Joy Schechtman, Edward J. Fudman, (unknown), Sheila Gujrathi, Robert G. Trapp, Nadera Sweiss, (unknown), Wolfgang Dummer, (unknown)	157
19	TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma 2006 ·European Respiratory Journal ·Mary K. Miller, (unknown), Paul D. Blanc, David J. Pasta, Sheila Gujrathi, Hal V. Barron, Sally E. Wenzel, Scott T. Weiss	63
20	Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma 2005 ·Annals of Allergy Asthma & Immunology ·Larry Borish, Bradley E. Chipps, Yamo Deniz, Sheila Gujrathi, Beiyao Zheng, Chantal Dolan	137

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact